A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

The optimal frequency of intravenous (IV) bisphosphonate administration is unclear. We thus performed a study evaluating the effects of switching from 3–4 to 12 weekly therapy in patients with biochemically defined low-risk bone metastases. Patients with serum C-telopeptide (CTx) levels ≤600 ng/L af...

Descripción completa

Detalles Bibliográficos
Autores principales: Addison, Christina L., Bouganim, Nathaniel, Hilton, John, Vandermeer, Lisa, Dent, Susan, Amir, Eitan, Hopkins, Sean, Kuchuk, Iryna, Segal, Roanne, Song, Xinni, Gertler, Stan, Mazzarello, Sasha, Dranitsaris, George, Ooi, Daylily, Pond, Gregory, Clemons, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962742/
https://www.ncbi.nlm.nih.gov/pubmed/24638849
http://dx.doi.org/10.1007/s10549-014-2906-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962742/
https://www.ncbi.nlm.nih.gov/pubmed/24638849
http://dx.doi.org/10.1007/s10549-014-2906-x

Ejemplares similares